Trial · NCT04937452
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 16 of 16
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Frontal Assessment Battery (FAB) | 24 weeks | Battery to evaluate executive functions. The scores range from 0-18 with a higher score meaning less cognitive impairment. |
| Secondary | Neuropsychiatric Inventory (NPI) scale | 24 weeks | Battery to assess behavioral changes. The scores range from 0-144 with a higher score meaning more severe behavioural disturbances. |
| Secondary | Frontal Behavioural Inventory (FBI) | 24 weeks | Battery to assess behavioral changes. The scores range from 0-72 with a higher score meaning more severe behavioural disturbances. |
| Secondary | Clinical Dementia Rating scale-Frontotemporal dementia Sum Of Boxes (CDR-FTDSOB) | 24 weeks | Battery to evaluate global disease severity. The scores range from 0-24 with a higher score meaning higher disease severity. |
| Secondary | Screening for aphasia in Neurodegeneration (SAND) scale | 24 weeks | Battery to evaluate language functions. The scores range from 0-84 with a higher score meaning less severe language deficits. |
| Secondary | Mini Mental State Examination (MMSE) | 24 weeks | battery to evaluate global cognition. The scores range from 0-30 with a higher score meaning less cognitive impairment. |
| Secondary | Addenbrooke's Cognitive Examination Revised (ACE-R) | 24 weeks | battery to evaluate global cognition. The scores range from 0-100 with a higher score meaning less cognitive impairment. |
| Secondary | Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL) | 24 weeks | battery to evaluate activities of daily living. The scores range from 0-78 with lower scores indicating more severe functional impairment. |
| Secondary | CGIC questionnaire | 24 weeks | questionnaire to evaluate clinically meaningful change |
| Secondary | 18F-FDG CT/PET | 24 weeks | Change in brain glucose metabolism will be measured via FDG-PET |
| Secondary | Long intracortical inhibition (LICI) | 24 weeks | TMS protocol to evaluate GABA(B)ergic transmission |
| Secondary | Short intracortical inhibition (SICI) | 24 weeks | TMS protocol to evaluate GABA(B)ergic transmission |
| Secondary | Short-Latency Afferent Inhibition (SAI) | 24 weeks | TMS protocol to evaluate cholinergic transmission |
| Secondary | Intermittent Theta Burst Stimulation (iTBS) | 24 weeks | TMS protocol to evaluate cortical plasticity |
| Secondary | TMS-EEG | 24 weeks | power in beta-gamma band to evaluate prefrontal cortical oscillatory activity |
| Secondary | Nature, frequency and severity of adverse events (AEs) | 24 weeks | To assess the safety and tolerability |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04937452/registered